New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
09:16 EDTCTICCell Therapeutics has opportunity in MF, says Roth Capital
After attending Cell Therapeutics' Analyst Day, Roth Capital believes the company's pacritinib drug has a material opportunity to become a treatment for myelofibrosis, or MF, given the drug's differentiated profile of having a minimal effect on platelets. The firm maintains a $4 price target and Buy rating on the stock.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
05:32 EDTCTICCTI BioPharma announces advancement of tosedostat LI-1 trial
Subscribe for More Information
November 23, 2015
09:18 EDTCTICOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tyson Foods (TSN), up 2.4%... Mallinckrodt (MNK), up 7.4%. ALSO HIGHER: Novocure (NVCR), up 16.8% after announcing new Phase 3 data from Optune study... CTI BioPharma (CTIC), up 12.7% after the initiation of its rolling new drug application to the FDA for pacritinib... Peabody Energy (BTU), up 14.8% after announcing an asset sale... Sarepta Therapeutics (SRPT), up 5.2% following a positive mention in Barron's. DOWN AFTER EARNINGS: Trina Solar (TSL), down 5.6%. ALSO LOWER: Par Pacific (PARR), down 13.2% after pricing its 3.4M registered direct offering at $22.00... Lions Gate (LGF), down 2.9% after the "Hunger Games" finale opens below the series average.
05:39 EDTCTICCTI BioPharma initiates rolling submission of U.S. NDA for pacritinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use